Review
CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections
Affiliations
- PMID: 15043387
Item in Clipboard
Review
CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections
Curr Opin Investig Drugs.
2004 Feb.
Abstract
Recent advances in immunology reveal that vertebrate innate immune systems use pattern-recognition receptors, of which the best characterized is the toll-like receptor (TLR) family, to specifically detect pathogen-associated molecular patterns (PAMPs) present in infectious agents. Based on this, use of synthetic PAMPs has attracted much interest for specific immunoprophylaxis and immunotherapy purposes. Among the PAMPs, immunostimulatory CpG DNA, a TLR9 ligand, displays promising potent immunostimulatory and adjuvanticity in different settings. In this review, recent developments in the use of CpG DNA for inducing immunity in the mucosal tissues will be highlighted.
Similar articles
-
Enhancing vaccines with immune stimulatory CpG DNA.Curr Opin Mol Ther. 2001 Feb;3(1):15-24. Curr Opin Mol Ther. 2001. PMID: 11249727 Review.
-
The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challenges.J Clin Virol. 2004 Jul;30(3):207-10. doi: 10.1016/j.jcv.2004.03.001. J Clin Virol. 2004. PMID: 15135735 Review.
-
CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.Int Immunopharmacol. 2006 Oct;6(10):1586-96. doi: 10.1016/j.intimp.2006.06.001. Epub 2006 Jun 28. Int Immunopharmacol. 2006. PMID: 16919831
-
Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.Immunol Lett. 2005 Mar 15;97(2):181-8. doi: 10.1016/j.imlet.2004.11.009. Epub 2004 Dec 7. Immunol Lett. 2005. PMID: 15752556 Review.
-
Immunopharmacology of CpG DNA.Biol Chem. 2002 Oct;383(10):1491-500. doi: 10.1515/BC.2002.171. Biol Chem. 2002. PMID: 12452427 Review.
Cited by
-
Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.Malar J. 2019 Apr 24;18(1):146. doi: 10.1186/s12936-019-2773-3. Malar J. 2019. PMID: 31014347 Free PMC article.
-
Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice.Infect Immun. 2019 May 21;87(6):e00911-18. doi: 10.1128/IAI.00911-18. Print 2019 Jun. Infect Immun. 2019. PMID: 30936155 Free PMC article.
-
Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research.Biomed Res Int. 2013;2013:282913. doi: 10.1155/2013/282913. Epub 2013 Apr 23. Biomed Res Int. 2013. PMID: 23710439 Free PMC article. Review.
-
Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin.Vaccine. 2009 Oct 19;27(44):6239-46. doi: 10.1016/j.vaccine.2009.07.108. Epub 2009 Aug 15. Vaccine. 2009. PMID: 19686693 Free PMC article.
-
Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.Vaccine. 2014 Dec 5;32(51):6934-6940. doi: 10.1016/j.vaccine.2014.10.051. Epub 2014 Nov 2. Vaccine. 2014. PMID: 25444819 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources